Pharmaceutical Business review

Transcept Pharma refiles Intermezzo NDA

Intermezzo is indicated for the treatment of insomnia or sleeping disorders.

The refiling of the application follows a meeting between Transcept and the FDA, to discuss the issues raised by the FDA in July 2011 Complete Response Letter.